-
1 Comment
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.3.
Based on the above factors, LENSAR, Inc gets an overall score of 1/5.
Industry | Medical Devices |
---|---|
Exchange | NASDAQ |
CurrencyCode | USD |
ISIN | US52634L1089 |
Sector | Healthcare |
Market Cap | 165M |
---|---|
PE Ratio | None |
Target Price | 15 |
Beta | 0.56 |
Dividend Yield | None |
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System. The company offers LENSAR Laser System which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for LNSR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025